国造药巨头默沙东（Merck & Co）近日在2016年第52届美国临床肿瘤学会（ASCO）年会上颁布了PD-1免疫疗法Keytruda（pembrolizumab）结合其他医治规划（蕴含癌症疫苗T-vec、dabrafenib+trametinib、低剂量ipilimumab）医治晚期玄色素瘤的3个钻研的数据。

The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic cancer. The pharmacokinetic study of Compound 55 was carried out by Medicilon.

The binding assay by surface plasmon resonance (SPR) analysis shows that WYC-209A and WYC-209B acid bind to RARs at nano-molar doses. SPR was carried out by Medicilon, using the Biacore 8K equipment.